Avalyn’s upsized IPO; Alector ends another study in GSK partnershipnews2026-04-30T15:33:40+00:00April 30th, 2026|Endpoints News|
Pfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenuenews2026-04-29T15:28:51+00:00April 29th, 2026|Endpoints News|
Rocket’s PRV goes for $180M; Oruka targets $500M offeringnews2026-04-28T14:54:36+00:00April 28th, 2026|Endpoints News|
Thermo Fisher sells microbiology biz; Ligand to buy XOMAnews2026-04-27T15:17:23+00:00April 27th, 2026|Endpoints News|
Avalyn plots $182M IPO; WHO prequalifies Novartis’ malaria drugnews2026-04-24T15:03:27+00:00April 24th, 2026|Endpoints News|
Novo’s pill for kids; Altimmune’s $225M offering; Merck teams with Google Cloudnews2026-04-23T14:27:09+00:00April 23rd, 2026|Endpoints News|
Nektar’s $325M offering; Maze stock rises; Merck deal rumors; BMS layoffsnews2026-04-22T15:28:02+00:00April 22nd, 2026|Endpoints News|
Carvykti shows promise before multiple myeloma; two megarounds; AstraZeneca wins twicenews2026-04-21T15:20:59+00:00April 21st, 2026|Endpoints News|
Merck partner reveals bispecific data; Biogen pays $100M for antibody rightsnews2026-04-20T15:51:00+00:00April 20th, 2026|Endpoints News|
Trevi raises $150M; Spain and Boston set up biotech fundnews2026-04-17T15:10:29+00:00April 17th, 2026|Endpoints News|
